Key facts
- QuantumCell’s last known valuation is $16.3M (Oct 2025).
- It has raised $5.7M; the latest was Early Stage VC ($5.7M) in Oct 2025.
- Notable investors include Lundbeckfonden BioCapital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for QuantumCell
- ·The full record, as it builds
Funding rounds
No funding rounds for QuantumCell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About QuantumCell
Developer of pharmaceutical products designed for medical treatment. The company focuses on the research, development, and commercialization of pharmaceuticals and related activities, enabling healthcare providers and patients to access therapies.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2025
- Employees
- 1
- Ownership
- Privately Held (backing)
QuantumCell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in QuantumCell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on QuantumCell in its N-PORT filings yet. We sweep new filings monthly.